Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASER-TBM in HIV-associated tuberculous meningitis
PACTR201902921101705Phase 2Recruiting
- Sponsor
- Wellcome Trust
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin, linezolid and aspirin in meningeal tuberculosis and human immunodeficiency virus infection (HIV) (3 arms), sponsored by Wellcome Trust. Primary endpoint: Incidence of solicited treatment-related adverse events and death at 56 days. Started Apr 2019; status: recruiting.
02
Drugs
rifampicinlinezolidaspirin
03
Conditions
meningeal tuberculosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201902921101705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201902921101705.